Retrospective comparison of efficacy and safety of docetaxel and weekly-paclitaxel as 2nd-line chemotherapy for patients with unresectable or recur...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter H. Nakatsumi
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors H. Nakatsumi1, Y. Komatsu1, K. Sawada2, T. Muranaka1, Y. Kawamoto1, S. Yuki2, N. Sakamoto2
  • 1Department of Cancer Center, Hokkaido University Hospital, Sapporo, Japan, /
  • 2Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan, /

Abstract

Efficacy and safety of docetaxel (DTX) or weekly-paclitaxel (wPTX) had been reported in single-arm phase II studies, and DTX or wPTX is widely used in clinical practice as second-line chemotherapy for patients with unresectable or recurrent esophageal cancer. However, there was no randomized controlled trial comparing DTX and wPTX. We investigated retrospectively the efficacy and safety of DTX and wPTX as second-line chemotherapy for patients with esophageal cancer in our institution.